Location History:
- Gistoux, BE (1992)
- Chaumont-Gistoux, BE (1992 - 2002)
- Louvain-La-neuve, BE (2008)
- Brussels, BE (2016 - 2024)
Company Filing History:
17 out of 525 
1 out of 1 
1 out of 541 
Years Active: 1992-2025
Title: Catherine Uyttenhove: Pioneering Innovator in Immunology
Introduction
Catherine Uyttenhove is a notable inventor based in Brussels, Belgium, renowned for her contributions to the field of immunology. With a remarkable portfolio of 18 patents, she has significantly impacted the diagnosis and treatment of various health conditions, particularly those related to cancer. Her innovative work focuses on specific antibodies that target transforming growth factor beta (TGF-β) isoforms, notably TGF-β1 and TGF-β3.
Latest Patents
Catherine's latest patents showcase her expertise in developing specific binding members, particularly antibodies and their fragments. Her patent on "TGF-β3 specific antibodies and methods and uses thereof" highlights antibodies that selectively bind to TGF-β3, providing tools for diagnosing and treating conditions linked to elevated TGF-β3 levels, such as cancer. These antibodies can modulate immune responses and may be used in conjunction with chemotherapeutics or other cancer therapies. Additionally, her work on "TGF-β1 specific antibodies and methods and uses thereof" introduces antibodies that specifically target TGF-β1, facilitating similar applications in cancer diagnosis and treatment. Key novel antibodies listed in her patents include MTGF-β3-9, MTGF-β3-12, MTGF-β3-16, MTGF-β3-17, MTGF-β3-19, and antibody 13A1.
Career Highlights
Catherine Uyttenhove has had a distinguished career, contributing her knowledge and expertise to notable institutions such as the Ludwig Institute for Cancer Research and the Department of Immunology at the Institut Henri Beaufour. Her research has consistently advanced the field of immunology, particularly in understanding TGF-β's role in cancer progression and immune modulation.
Collaborations
Throughout her career, Catherine has collaborated with esteemed professionals in the field, including Jacques Van Snick and Thierry Boon. These partnerships have fostered advancements in research, enabling innovative solutions for tackling challenging health issues.
Conclusion
Catherine Uyttenhove exemplifies the spirit of innovation and dedication to scientific progress. Her extensive patent portfolio and collaborative efforts in immunology illustrate her commitment to advancing healthcare solutions. Through her groundbreaking work, she continues to inspire future generations of inventors and researchers in the quest to combat cancer and improve patient outcomes.